Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms

Precision medicine approaches such as ex vivo drug sensitivity screening (DSS) are appealing to inform rational drug selection in myelodysplastic syndromes (MDSs) and acute myeloid leukemia, given their marked biologic heterogeneity. We evaluated a novel, fully automated ex vivo DSS platform that us...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood Adv
Hlavní autoři: Spinner, Michael A., Aleshin, Alexey, Santaguida, Marianne T., Schaffert, Steven A., Zehnder, James L., Patterson, A. Scott, Gekas, Christos, Heiser, Diane, Greenberg, Peter L.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2020
Témata:
Myeloid Neoplasia
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7322964/
https://ncbi.nlm.nih.gov/pubmed/32569379
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020001934
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky